Scrip
AstraZeneca's Recentin fails to show benefit over Roche's Avastin in Phase III colorectal cancer trial
09 March 2010
Malini Guha
Please Login to read the full article.
09 March 2010
Malini Guha
AstraZeneca is facing more disappointment with the development of its new anticancers after its experimental anti-angiogenic drug Recentin (cediranib) did not show non-inferiority in progression-free survival (PFS), or superiority, to
Roche's Avastin (bevacizumab) when both were combined...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Amgen's Vectibix yields mixed results in second-line Phase III colorectal cancer trial
- Amgen's Vectibix meets goal in pivotal first-line trial in colorectal cancer
- Nexavar fails second Phase III trial in newly diagnosed advanced lung cancer
- Avastin meets goal in first Phase III trial in ovarian cancer
